
What is claimed is:

1. A compound of Formula I



I

or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the  group together with the N atom and the C atom to which it is attached forms a 5 membered ring, wherein the ring is aromatic, unsaturated, partially saturated, or saturated;

x, y, and z are independently selected from CR, CRR', N, NR'', O, $S(O)_n$, C=O, C=S, and C=NH;

each R and R' are independently selected from H, halogen, -OH, -CN, $-CO(C_{1-4}alkyl)$, $-S(O)_n(C_{1-4}alkyl)$, -COOH, $-COO(C_{1-4}alkyl)$, $-CONH_2$, $-CONH(C_{1-4}alkyl)$, $-CO(diC_{1-4}alkylamino)$, $-NH_2$, $C_{1-4}alkylamino$, $diC_{1-4}alkylamino$, $-NH(COC_{1-4}alkyl)$, $-N(C_{1-4}alkyl)C(=O)F$, $C_{1-4}alkyl$, $-(CH_2)_m(C_{3-5}cycloalkyl)$, $-CH_2(C_{3-5}heterocycloalkyl)$, $C_{1-4}deuteroalkyl$, $C_{3-5}cycloalkyl$, $C_{3-4}heterocycloalkyl$, $C_{2-4}alkenyl$, $C_{2-4}alkynyl$, $C_{1-4}alkoxy$, $C_{1-4}deuteroalkoxy$, phenyl, 5-membered heteroaryl, and 6-membered heteroaryl;

wherein the $C_{1-4}alkyl$ group is optionally substituted with 1 to 4 F or optionally substituted with a substituent selected from –OH, -CN, $C_{1-4}alkoxy$, $-NH_2$, $C_{1-4}alkylamino$, $diC_{1-4}alkylamino$, and $-S(O)_n(C_{1-4}alkyl)$;

wherein the $C_{1-4}alkoxy$ group is optionally substituted with 1 to 4 independently selected halogens or optionally substituted with a substituent selected from –OH, -CN, $C_{1-4}alkoxy$, $-NH_2$, $C_{1-4}alkylamino$, $diC_{1-4}alkylamino$, and $-S(O)_n(C_{1-4}alkyl)$;

wherein the $-CH_2(C_{3-5}cycloalkyl)$, $C_{3-4}heterocycloalkyl$, phenyl, 5-membered heteroaryl, and 6-membered heteroaryl groups are optionally substituted with 1 to 4

substituents independently selected from halogen, –OH, -CN, C_{1-4}alkoxy, C_{1-4}alkyl, -NH_2, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -$S(O)_n(C_{1-4}$alkyl); and




wherein R of a first CR or CRR' group and R of a second CR or CRR' group, if present, together with the atoms to which they are attached, form a C_{3-5}carbocycle;

each R'' is independently selected from H, -OH, –$CO(C_{1-4}$alkyl), –$S(O)_n(C_{1-4}$alkyl), -$COO(C_{1-4}$alkyl), -$CONH_2$, -$CONH(C_{1-4}$alkyl), -$CO(diC_{1-4}$alkylamino), C_{1-4}alkyl, -$(CH_2)_m(C_{3-5}$cycloalkyl), -$CH_2(C_{3-5}$heterocycloalkyl), C_{1-4}deuteroalkyl, C_{3-5}cycloalkyl, C_{3-4}heterocycloalkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, phenyl, 5-membered heteroaryl, and 6-membered heteroaryl;

wherein the C_{1-4}alkyl group is optionally substituted with 1 to 4 F or optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, -NH_2, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -$S(O)_n(C_{1-4}$alkyl); and

wherein the –$(CH_2)_m(C_{3-5}$cycloalkyl), C_{3-4}heterocycloalkyl, phenyl, 5-membered heteroaryl, and 6-membered heteroaryl groups are optionally substituted with 1 to 4 substituents independently selected from halogen, –OH, -CN, C_{1-4}alkoxy, C_{1-4}alkyl, -NH_2, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -$S(O)_n(C_{1-4}$alkyl);

R^1 is O, S, or NH;




R^2 is , , or , wherein

Ring A is a 5-membered heteroaryl containing one heteroatom selected from N, S, and O and optionally one or two further N atoms with the remaining ring atoms of the 5-membered heteroaryl being carbon, wherein

i) Ring A is attached via a C atom to the bicyclic core and R^3 is attached via an N atom; or

ii) Ring A is attached via an N atom to the bicyclic core and R^3 is attached via a C atom; or

iii) Ring A is attached via a C atom to the bicyclic core and R^3 is attached via a C atom;

and wherein the , , or  portion of R^2 is further optionally substituted with one or two independently selected substituents $R^{3'}$;




R^3 is C_{1-6}alkyl, C_{3-5}cycloalkyl, C_{2-6}alkoxy, C_{1-6}alkylamino, diC_{1-6}alkylamino, -$S(O)_n(C_{1-6}$alkyl), -$CH_2(C_{3-5}$cycloalkyl), -$OCH_2(C_{3-5}$cycloalkyl), -$NHCH_2(C_{3-5}$cycloalkyl), -$S(O)_nCH_2(C_{3-5}$cycloalkyl), -$CH_2(C_{3-5}$heterocycloalkyl), or phenyl; wherein the C_{1-6}alkyl, C_{3-5}cycloalkyl, C_{2-6}alkoxy, C_{1-6}alkylamino, diC_{1-6}alkylamino, -$S(O)_n(C_{1-6}$alkyl), -$CH_2(C_{3-5}$cycloalkyl), -$OCH_2(C_{3-5}$cycloalkyl), -$NHCH_2(C_{3-5}$cycloalkyl), and -$S(O)_nCH_2(C_{3-5}$cycloalkyl) groups are optionally substituted with 1-9 halogen atoms and are optionally substituted with –CN and wherein the phenyl is optionally substituted with 1-3 substituents selected from halogen, C_{1-4}alkyl, C_{1-4}haloalkyl, C_{1-4}alkoxy, and C_{1-4}haloalkoxy;




$R^{3'}$ is independently halogen, C_{1-4}alkyl, C_{1-4}haloalkyl, C_{1-4}alkoxy, or C_{1-4}haloalkoxy;





R^4 is C_{1-3}alkyl, C_{1-4}haloalkyl, C_{1-4}alkoxy, C_{1-4}haloalkoxy, C_{3-5}cycloalkyl, or C_{3-5}cyclohaloalkyl;

n is 0, 1, or 2; and

m is 1 or 2; provided that

(1) if  is  then R^2 is not ;

(2) if  is  then R^2 is not ;

(3) if  is  or  then R^2 is not ; and

(4) if any of R, R' or R'' is phenyl then R^3 is not an unsubstituted C_{1-6}alkyl and R^3 is not C_{1-2}alkoxy.

2. The compound according to Claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the compound is not

1,3,3-trimethyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,2H,3H,5H-imidazo[1,2-a]pyrimidine-2,5-dione;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(pyrimidin-5-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one; or

2-[(methylamino)methyl]-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one.


3. The compound according to Claim 1 or Claim 2, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

x, y, and z are independently selected from CR, N, and NR''.


4. The compound according to Claim 1 or Claim 2, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

x, y, and z are independently selected from CR, N, and S.


5. The compound according to Claim 1 or Claim 2, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein



6. The compound according to Claim 1 or Claim 2, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein



7. The compound according to Claim 1 or Claim 2, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein



8. The compound according to any one of Claims 1-7, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R and R', if present, are independently selected from H, halogen, -COO(C_{1-4}alkyl), C_{1-4}alkyl, -$(CH_2)_m$(C_{3-5}cycloalkyl), -CH_2(C_{3-5}heterocycloalkyl), C_{1-4}deuteroalkyl, C_{3-5}cycloalkyl, C_{3-4}heterocycloalkyl, C_{2-4}alkynyl, C_{1-4}alkoxy, phenyl, 5-membered heteroaryl, and 6-membered heteroaryl;

wherein the C_{1-4}alkyl group is optionally substituted with 1 to 4 F or optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, C_{1-4}alkylamino, and diC_{1-4}alkylamino; and

wherein the $-(CH_2)_m(C_{3-5}$cycloalkyl), 5-membered heteroaryl, and 6-membered heteroaryl groups are optionally substituted with 1 to 4 substituents independently selected from halogen, –OH, and C_{1-4}alkyl.

9. The compound according to any one of Claims 1-7, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R and R', if present, are independently selected from H, halogen, C_{1-4}alkyl, C_{1-4}deuteroalkyl, and C_{1-4}alkoxy; wherein the C_{1-4}alkyl group is optionally substituted with a substituent selected from –OH and -CN.

10. The compound according to any one of Claims 1-7, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R and R', if present, are independently selected from H and C_{1-4}alkyl.

11. The compound according to any one of Claims 1-7, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R and R', if present, are independently selected from H, F, Cl, -COOMe, methyl, ethyl, isopropyl, fluoromethyl, trifluoromethyl, $-CH_2OH$, 2-hydroxyethyl, 2-hydroxy-2-methylpropyl, $-CH_2CN$, 2-hydroxypropyl, $-CH_2OCH_3$, $-CH_2CH_2OCH_3$, methylaminomethyl, dimethylaminomethyl, 2-(dimethylamino)ethyl, cyclopropylmethyl, (2,2-difluorocyclopropyl)methyl, (3,3-difluorocyclobutyl)methyl, (1-hydroxycyclopropyl)ethyl, $-CD_3$, cyclopropyl, (oxetan-3-yl)methyl, oxetan-3-yl, prop-2-yn-1-yl, methoxy, phenyl, pyrazolyl, 1-methyl-pyrazol-4-yl, pyridinyl, pyrazinyl, pyrimidinyl, 6-methylpyridin-2-yl, and 6-chloropyridin-2-yl.

12. The compound according to any one of Claims 1-7, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R and R', if present, are independently selected from H, Cl, methyl, $-CH_2OH$, 2-hydroxyethyl, $-CH_2CN$, $-CD_3$, and methoxy.

13. The compound according to any one of Claims 1-7, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R and R', if present, are independently selected from H and methyl.

14. The compound according to any one of Claims 1-13, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R'', if present, is independently selected from H, -COO(C_{1-4}alkyl), C_{1-4}alkyl, -$(CH_2)_m$(C_{3-5}cycloalkyl), -CH_2(C_{3-5}heterocycloalkyl), C_{1-4}deuteroalkyl, C_{3-5}cycloalkyl, C_{3-4}heterocycloalkyl, C_{2-4}alkynyl, phenyl, 5-membered heteroaryl, and 6-membered heteroaryl;

wherein the C_{1-4}alkyl group is optionally substituted with 1 to 4 F or optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, C_{1-4}alkylamino, and diC_{1-4}alkylamino; and

wherein the –$(CH_2)_m$(C_{3-5}cycloalkyl), 5-membered heteroaryl, and 6-membered heteroaryl groups are optionally substituted with 1 to 4 substituents independently selected from halogen, –OH, and C_{1-4}alkyl.

15. The compound according to any one of Claims 1-13, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R'', if present, is independently selected from H, C_{1-4}alkyl, and C_{1-4}deuteroalkyl; wherein the C_{1-4}alkyl group is optionally substituted with a substituent selected from –OH and -CN.

16. The compound according to any one of Claims 1-13, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R'', if present, is independently selected from H and C_{1-4}alkyl.

17. The compound according to any one of Claims 1-13, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R'', if present, is independently selected from H, -COOMe, methyl, ethyl, isopropyl, fluoromethyl, trifluoromethyl, 2-hydroxyethyl, 2-hydroxy-2-methylpropyl, -CH_2CN, 2-hydroxypropyl, -CH_2OCH_3, -$CH_2CH_2OCH_3$, dimethylaminomethyl, 2-(dimethylamino)ethyl, cyclopropylmethyl, (2,2-difluorocyclopropyl)methyl, (3,3-

difluorocyclobutyl)methyl, (1-hydroxycyclopropyl)ethyl, -CD_3, cyclopropyl, (oxetan-3-yl)methyl, oxetan-3-yl, prop-2-yn-1-yl, phenyl, pyrazolyl, 1-methyl-pyrazol-4-yl, pyridinyl, pyrazinyl, pyrimidinyl, 6-methylpyridin-2-yl, and 6-chloropyridin-2-yl.

18. The compound according to any one of Claims 1-13, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R'', if present, is independently selected from H, methyl, 2-hydroxyethyl, -CH_2CN, and -CD_3.

19. The compound according to any one of Claims 1-13, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

each R'', if present, is independently selected from H and methyl.

20. The compound according to any one of Claims 1-19, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R of a first CR or CRR' group and R of a second CR or CRR' group, if present, together with the atoms to which they are attached, form a cyclopropyl.


21. The compound according to any one of Claims 1-20, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^1 is O or S.


22. The compound according to any one of Claims 1-20, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^1 is O.


23. The compound according to any one of Claims 1-22, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^2 is .

24. The compound according to any one of Claims 1-22, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^2 is .

25. The compound according to any one of Claims 1-22, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein



R^2 is , wherein A is a 5-membered heteroaryl containing two N atoms.

26. The compound according to any one of Claims 1-22, 24, and 25, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein A is attached via a C atom to the bicyclic core and R^3 is attached via an N atom.


27. The compound according to any one of Claims 1-22, 24, and 25, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein A is attached via an N atom to the bicyclic core and R^3 is attached via an C atom.

28. The compound according to any one of Claims 1-22, 24, and 25, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein A is attached via a C atom to the bicyclic core and R^3 is attached via a C atom.




29. The compound according to any one of Claims 1-22, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein




R^2 is  or .




30. The compound according to any one of Claims 1-22, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^2 is .

31. The compound according to any one of Claims 1-30, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the

, , or  portion of R^2 is not further optionally substituted with one or two independently selected substituents $R^{3'}$.

32. The compound according to any one of Claims 1-30, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the , , or  portion of R^2 is substituted with one or two independently selected substituents $R^{3'}$.

33. The compound according to any one of Claims 1-33, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the , , or  portion of R^2 is substituted with one substituent $R^{3'}$.

34. The compound according to any one of Claims 1-33, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^3 is $C_{1\text{-}6}$alkyl, $C_{2\text{-}6}$alkoxy, -CH_2($C_{3\text{-}5}$cycloalkyl), -OCH_2($C_{3\text{-}5}$cycloalkyl), -CH_2($C_{3\text{-}5}$heterocycloalkyl), or phenyl; wherein the $C_{1\text{-}6}$alkyl, $C_{2\text{-}6}$alkoxy, -CH_2($C_{3\text{-}5}$cycloalkyl), and -OCH_2($C_{3\text{-}5}$cycloalkyl) groups are optionally substituted with 1-9 halogen atoms and are optionally substituted with –CN and wherein the phenyl is optionally substituted with one halogen substituent.

35. The compound according to any one of Claims 1-33, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^3 is $C_{1\text{-}6}$alkyl, $C_{2\text{-}6}$alkoxy, -CH_2($C_{3\text{-}5}$cycloalkyl), or -CH_2($C_{3\text{-}5}$heterocycloalkyl); wherein the $C_{1\text{-}6}$alkyl, $C_{2\text{-}6}$alkoxy, and -CH_2($C_{3\text{-}5}$cycloalkyl) groups are optionally substituted with 1-9 halogen atoms.

36. The compound according to any one of Claims 1-33, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^3 is C_{1-6}alkyl, C_{2-6}alkoxy, -CH_2(C_{3-5}cycloalkyl), or -CH_2(C_{3-5}heterocycloalkyl); wherein the C_{1-6}alkyl, C_{2-6}alkoxy, and -CH_2(C_{3-5}cycloalkyl) groups are substituted with 2-5 halogen atoms.

37. The compound according to any one of Claims 1-33, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^3 is 2,2,2-trifluoroethyl, propyl, 2,2-difluoropropyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, 2,2,3,3,3-pentafluoropropyl, -OCH_2CN, -$OC(CH_3)_2CN$, difluoromethoxy, trifluoromethoxy, -$OCH(CN)CH_3$, 2-fluoroethoxy, 2,2,-difluoroethoxy, 2,2,2-trifluoroethoxy, 2,2-difluoropropoxy, 2,2,3,3-tetrafluoropropoxy, 2,2,3,3,3-pentafluoropropoxy, cyclopropylmethyl, (2,2-difluorocyclopropyl)methyl, (3,3-difluorocyclobutyl)methyl, cyclopropylmethoxy, (2,2-difluorocyclopropyl)methoxy, (oxetan-3-yl)methyl, phenyl, 3-fluorophenyl, or 4-fluorophenyl.

38. The compound according to any one of Claims 1-33, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^3 is 3,3,3-trifluoropropyl, 2,2,3,3,3-pentafluoropropyl, 2,2,2-trifluoroethoxy, or (2,2-difluorocyclopropyl)methyl.

39. The compound according to any one of Claims 1-30 and 32-38, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

$R^{3'}$ is independently halogen or C_{1-4}alkyl.

40. The compound according to any one of Claims 1-30 and 32-38, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

$R^{3'}$ is independently F or methyl.

41. The compound according to any one of Claims 1-40, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^4 is C_{1-3}alkyl, C_{1-4}haloalkyl, C_{1-4}alkoxy, or C_{3-5}cycloalkyl.

42. The compound according to any one of Claims 1-40, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^4 is C_{1-4}haloalkyl.

43. The compound according to any one of Claims 1-40, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^4 is methyl, ethyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, or cyclopropyl.

44. The compound according to any one of Claims 1-40, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

R^4 is trifluoromethyl.

45. The compound according to any one of Claims 1-44, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

n is 0.

46. The compound according to any one of Claims 1-44, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

n is 1.

47. The compound according to any one of Claims 1-44, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

n is 2.

48. The compound according to any one of Claims 1-47, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

m is 1.

49. The compound according to any one of Claims 1-47, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein

m is 2.

50. The compound according to Claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the compound is

6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,2H,3H,5H-imidazo[1,2-a]pyrimidine-2,5-dione;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

3-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-3,7-bis(trifluoromethyl)-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

2-fluoro-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

2-chloro-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

2-(methoxymethyl)-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-cyclopropyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-cyclopropyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2,3-dimethyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-5-(trifluoromethyl)-3H,7H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one;

2,3-dimethyl-5-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-3H,7H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one;

7-ethyl-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

1,2-dimethyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-5-(trifluoromethyl)-1H,7H-pyrazolo[1,5-a]pyrimidin-7-one;

1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-5-(trifluoromethyl)-1H,7H-pyrazolo[1,5-a]pyrimidin-7-one;

1,3-dimethyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-5-(trifluoromethyl)-1H,7H-pyrazolo[1,5-a]pyrimidin-7-one;

3-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-2-(trifluoromethyl)-4H,6H,7H,8H-pyrrolo[1,2-a]pyrimidin-4-one;

2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-(trifluoromethyl)-3-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-4H,6H,7H,8H-pyrrolo[1,2-a]pyrimidin-4-one;

6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-2H,3H,5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

6-{1-[(2,2-difluorocyclopropyl)methyl]-1H-pyrazol-4-yl}-2-methyl-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-2H,3H,5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

8-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-9-(trifluoromethyl)-6,10-diazatricyclo[4.4.0.0^{2,4}]deca-1(10),8-dien-7-one;

6-{1-[(3,3-difluorocyclobutyl)methyl]-1H-pyrazol-4-yl}-2-methyl-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-[1,2,4]triazolo[4,3-a]pyrimidin-5-one;

3-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-5-(trifluoromethyl)-3H,7H-[1,2,3,4]tetrazolo[1,5-a]pyrimidin-7-one;

2-methyl-6-{1-[(oxetan-3-yl)methyl]-1H-pyrazol-4-yl}-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-3-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

2-(hydroxymethyl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

2-(hydroxymethyl)-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

2-chloro-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(propan-2-yl)-7-(trifluoromethyl)-1H,2H,3H,5H-imidazo[1,2-a]pyrimidine-2,5-dione;

1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

3-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-5-(trifluoromethyl)-3H,7H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3]oxazolo[3,2-a]pyrimidin-5-one;

2-methyl-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

7-ethoxy-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-(methoxymethyl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-methoxy-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

3-chloro-1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-(hydroxymethyl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-(hydroxymethyl)-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,2H,3H,5H-imidazo[1,2-a]pyrimidine-2,5-dione;

2-chloro-1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-chloro-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-cyclopropyl-1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-chloro-1-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-(methoxymethyl)-1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-ethyl-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(2-methoxyethyl)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(propan-2-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-{1-[(2,2-difluorocyclopropyl)methyl]-1H-pyrazol-4-yl}-1,2-dimethyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-{1-[(3,3-difluorocyclobutyl)methyl]-1H-pyrazol-4-yl}-1,2-dimethyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-[1-(cyclopropylmethyl)-1H-pyrazol-4-yl]-1,2-dimethyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(cyclopropylmethyl)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-(methoxymethyl)-1-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(2-hydroxypropyl)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-6-{1-[(oxetan-3-yl)methyl]-1H-pyrazol-4-yl}-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(cyclopropylmethyl)-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-[2-(dimethylamino)ethyl]-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(cyclopropylmethyl)-2-methyl-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-[2-(dimethylamino)ethyl]-2-methyl-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-3-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methoxy-1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methoxy-1-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-{1-[(2,2-difluorocyclopropyl)methyl]-1H-pyrazol-4-yl}-2-methyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-($^{2}H_3$)methyl-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-($^{2}H_3$)methyl-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(2-hydroxyethyl)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

methyl 2-methyl-5-oxo-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidine-1-carboxylate;

1-[(2,2-difluorocyclopropyl)methyl]-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-[(3,3-difluorocyclobutyl)methyl]-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(2-hydroxyethyl)-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-[2-(dimethylamino)ethyl]-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(prop-2-yn-1-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-{2-methyl-5-oxo-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-1-yl}acetonitrile;

2-[2-methyl-5-oxo-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-1-yl]acetonitrile;

1-(2-hydroxy-2-methylpropyl)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-[2-(1-hydroxycyclopropyl)ethyl]-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-1-[(oxetan-3-yl)methyl]-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-1-(oxetan-3-yl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidine-5-thione;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(pyridin-2-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-1-(pyridin-2-yl)-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(pyrazin-2-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-1-(6-methylpyridin-2-yl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-1-(1-methyl-1H-pyrazol-4-yl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(pyridin-3-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-phenyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(6-chloropyridin-2-yl)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(pyridin-4-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-1-(1H-pyrazol-4-yl)-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-(fluoromethyl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-[(dimethylamino)methyl]-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

6-(1-{[(1R)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-2-methyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-(1-{[(1S)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-2-methyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-(1-{[(1R)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-1,2-dimethyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-(1-{[(1S)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-1,2-dimethyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

6-(1-{[(1R)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-2-methyl-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

6-(1-{[(1S)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-2-methyl-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

(2R)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-2H,3H,5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

(2S)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-2H,3H,5H,6H,7H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;

1-{[(1R)-2,2-difluorocyclopropyl]methyl}-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one; or

1-{[(1S)-2,2-difluorocyclopropyl]methyl}-2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one.

51. The compound according to Claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the compound is

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-methoxy-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-(hydroxymethyl)-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one;

2-chloro-1-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1,2-dimethyl-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

2-methyl-6-[4-(2,2,2-trifluoroethoxy)phenyl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-($^2H_3$)methyl-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;

1-(2-hydroxyethyl)-2-methyl-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one;


2-{2-methyl-5-oxo-6-[1-(2,2,3,3,3-pentafluoropropyl)-1H-pyrazol-4-yl]-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-1-yl}acetonitrile;

2-[2-methyl-5-oxo-7-(trifluoromethyl)-6-[1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl]-1H,5H-imidazo[1,2-a]pyrimidin-1-yl]acetonitrile;

6-(1-{[(1R)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-2-methyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one; or


6-(1-{[(1S)-2,2-difluorocyclopropyl]methyl}-1H-pyrazol-4-yl)-2-methyl-7-(trifluoromethyl)-1H,5H-imidazo[1,2-a]pyrimidin-5-one.

52. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is




.


53. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is




54. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is




55. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is



56. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is




57. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is




.

58. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is



.


59. The compound according to Claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the compound is




.

60. The compound according to Claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the compound


is




61. The compound according to Claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the compound is




62. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is




63. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is




64. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is




65. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is



66. The compound according to Claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the compound is



67. The compound according to Claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, wherein the compound is



68. A pharmaceutical composition comprising the compound according to any one of Claims 1-67, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, and a pharmaceutically acceptable excipient.

69. A compound according to any one of Claims 1-67, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 68 for use as a medicament.

70. A compound according to any one of Claims 1-67, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 68 for use in reducing the body weight of a subject.

71. A compound according to any one of Claims 1-67, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 68 for use in reducing the body-mass-index of a subject.

72. A compound according to any one of Claims 1-67, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 68 for use in treating a metabolic disorder.

73. A compound according to any one of Claims 1-67, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 68 for use in treating a cardiovascular disorder.

74. A compound according to any one of Claims 1-67, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 68 for use in treating diabetes.

75. A compound according to any one of Claims 1-67, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 68 for use in treating obesity.

76. A compound according to any one of Claims 1-67, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 68 for use in treating dyslipidemia.

77. A compound according to any one of Claims 1-67, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 68 for use in treating non-alcoholic steatohepatitis (NASH).

78. Use of the compound according to any one of Claims 1-67, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 68 in the preparation of a medicament for reducing the body weight or the body-mass-index of a subject.

79. Use of the compound according to any one of Claims 1-67, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 68 in the preparation of a medicament for treating a metabolic or a cardiovascular disorder.


80. Use of the compound according to any one of Claims 1-67, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer, or the pharmaceutical composition according to Claim 68 in the preparation of a medicament for treating diabetes, obesity, dyslipidemia, or non-alcoholic steatohepatitis (NASH).

81. A method of reducing the body weight or the body-mass-index of a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according to any one of Claims 1-67, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

82. A method of treating a metabolic or cardiovascular disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according to any one of Claims 1-67, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

83. A method of treating diabetes, obesity, dyslipidemia, or non-alcoholic steatohepatitis (NASH) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound according to any one of Claims 1-67, or a tautomer thereof, or a pharmaceutically acceptable salt of said compound or said tautomer.

84. A compound of Formula I-1



I-1

wherein

X is H or Br;

R^1 is O, S, or NH; and

R is H, F, Cl, -OH, -CN, –CO(C_{1-4}alkyl), –S(O)$_n$(C_{1-4}alkyl), -COOH, -COO(C_{1-4}alkyl), -CONH$_2$, -CONH(C_{1-4}alkyl), -CO(diC_{1-4}alkylamino), -NH(COC_{1-4}alkyl), -N(C_{1-4}alkyl)C(=O)F, C_{1-4}alkyl, -(CH$_2$)$_m$(C_{3-5}cycloalkyl), -CH$_2$(C_{3-5}heterocycloalkyl), C_{1-4}deuteroalkyl, C_{3-5}cycloalkyl, C_{3-4}heterocycloalkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{1-4}deuteroalkoxy, 5-membered heteroaryl, or 6-membered heteroaryl;

wherein the C_{1-4}alkyl group is optionally substituted with 1 to 4 F or optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, -NH$_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -S(O)$_n$(C_{1-4}alkyl);

wherein the C_{1-4}alkoxy group is optionally substituted with 1 to 4 independently selected halogens or optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, -NH$_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -S(O)$_n$(C_{1-4}alkyl); and

wherein the -CH$_2$(C_{3-5}cycloalkyl), C_{3-4}heterocycloalkyl, 5-membered heteroaryl, and 6-membered heteroaryl groups are optionally substituted with 1 to 4 substituents independently selected from halogen, –OH, -CN, C_{1-4}alkoxy, C_{1-4}alkyl, -NH$_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -S(O)$_n$(C_{1-4}alkyl).

85. The compound of Claim 84, wherein X is H.

86. The compound of Claim 84, wherein X is Br.


87. The compound of any one of Claims 84-86, wherein R^1 is O.

88. The compound of any one of Claims 84-87, wherein R is methyl.

89. The compound of any one of Claims 84-87, wherein R is methoxy.

90. The compound of any one of Claims 84-87, wherein R is hydroxymethyl.

91. A compound of Formula I-2



I-2

or a tautomer thereof, wherein

X is H or Br;

R^1 is O, S, or NH;

R is H, halogen, -OH, -CN, –CO(C_{1-4}alkyl), –S(O)$_n$(C_{1-4}alkyl), -COOH, -COO(C_{1-4}alkyl), -CONH$_2$, -CONH(C_{1-4}alkyl), -CO(diC_{1-4}alkylamino), -NH$_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, -NH(COC$_{1-4}$alkyl), -N(C_{1-4}alkyl)C(=O)F, C_{1-4}alkyl, -(CH$_2$)$_m$(C_{3-5}cycloalkyl), -CH$_2$(C_{3-5}heterocycloalkyl), C_{1-4}deuteroalkyl, C_{3-5}cycloalkyl, C_{3-4}heterocycloalkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, C_{1-4}deuteroalkoxy, phenyl, 5-membered heteroaryl, and 6-membered heteroaryl;

wherein the C_{1-4}alkyl group is optionally substituted with 1 to 4 F or optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, -NH$_2$, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -S(O)$_n$(C_{1-4}alkyl);

wherein the C_{1-4}alkoxy group is optionally substituted with 1 to 4 independently selected halogens or optionally substituted with a substituent selected

from –OH, -CN, C_{1-4}alkoxy, -NH_2, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -$S(O)_n(C_{1-4}$alkyl); and

wherein the -$CH_2(C_{3-5}$cycloalkyl), C_{3-4}heterocycloalkyl, phenyl, 5-membered heteroaryl, and 6-membered heteroaryl groups are optionally substituted with 1 to 4 substituents independently selected from halogen, –OH, -CN, C_{1-4}alkoxy, C_{1-4}alkyl, -NH_2, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -$S(O)_n(C_{1-4}$alkyl); and

R'' is H, 2-trimethylsilylethoxymethyl, -OH, –$CO(C_{1-4}$alkyl), –$S(O)_n(C_{1-4}$alkyl), -$COO(C_{1-4}$alkyl), -$CONH_2$, -$CONH(C_{1-4}$alkyl), -CO(diC_{1-4}alkylamino), C_{1-4}alkyl, -$(CH_2)_m(C_{3-5}$cycloalkyl), -$CH_2(C_{3-5}$heterocycloalkyl), C_{1-4}deuteroalkyl, C_{3-5}cycloalkyl, C_{3-4}heterocycloalkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, phenyl, 5-membered heteroaryl, or 6-membered heteroaryl;

wherein the C_{1-4}alkyl group is optionally substituted with 1 to 4 F or optionally substituted with a substituent selected from –OH, -CN, C_{1-4}alkoxy, -NH_2, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -$S(O)_n(C_{1-4}$alkyl); and

wherein the –$(CH_2)_m(C_{3-5}$cycloalkyl), C_{3-4}heterocycloalkyl, phenyl, 5-membered heteroaryl, and 6-membered heteroaryl groups are optionally substituted with 1 to 4 substituents independently selected from halogen, –OH, -CN, C_{1-4}alkoxy, C_{1-4}alkyl, -NH_2, C_{1-4}alkylamino, diC_{1-4}alkylamino, and -$S(O)_n(C_{1-4}$alkyl);

with the proviso that if X is H and R'' is not 2-trimethylsilylethoxymethyl, then R is not H, C_{1-4}alkyl, or phenyl.

92. The compound of Claim 91, or a tautomer thereof, wherein X is H.

93. The compound of Claim 91, or a tautomer thereof, wherein X is Br.

94. The compound of any one of Claims 91-93, or a tautomer thereof, wherein R^1 is O.

95. The compound of any one of Claims 93-94, or a tautomer thereof, wherein R is H.

96. The compound of any one of Claims 93-94, or a tautomer thereof, wherein R is Cl.

97. The compound of any one of Claims 93-94, or a tautomer thereof, wherein R is hydroxymethyl.

98. The compound of any one of Claims 93-94, or a tautomer thereof, wherein R is methyl.

99. The compound of any one of Claims 91-98, or a tautomer thereof, wherein R'' is H.

100. The compound of any one of Claims 91-98, or a tautomer thereof, wherein R'' is methyl.

101. The compound of any one of Claims 91-98, or a tautomer thereof, wherein R'' is CD_3.

102. The compound of any one of Claims 91-98, or a tautomer thereof, wherein R'' is $-CH_2CH_2OH$.

103. The compound of any one of Claims 91-98, or a tautomer thereof, wherein R'' is $-CH_2CN$.

104. A compound, wherein the compound is 1-(2,2,3,3,3-pentafluoropropyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole.